La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Nuo Therapeutics Gestion
Gestion contrôle des critères 3/4
Nuo Therapeutics' CEO is David Jorden, appointed in May 2015, has a tenure of 9.25 years. total yearly compensation is $225.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 4.34% of the company’s shares, worth $789.75K. The average tenure of the management team and the board of directors is 7.3 years and 13.7 years respectively.
Informations clés
David Jorden
Directeur général
US$225.0k
Rémunération totale
| Pourcentage du salaire du PDG | 100.0% |
| Durée du mandat du directeur général | 9.3yrs |
| Propriété du PDG | 4.3% |
| Durée moyenne d'occupation des postes de direction | 7.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 13.7yrs |
Mises à jour récentes de la gestion
Recent updates
Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$3m |
| Mar 31 2024 | n/a | n/a | -US$3m |
| Dec 31 2023 | US$225k | US$225k | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$3m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | -US$4m |
| Dec 31 2022 | US$171k | US$169k | -US$3m |
| Sep 30 2022 | n/a | n/a | -US$3m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | -US$1m |
| Dec 31 2021 | n/a | n/a | -US$886k |
| Sep 30 2021 | n/a | n/a | US$8m |
| Dec 31 2020 | US$55k | n/a | US$8m |
| Sep 30 2020 | n/a | n/a | US$201k |
| Dec 31 2019 | US$141k | US$92k | -US$1m |
| Sep 30 2019 | n/a | n/a | -US$884k |
| Jun 30 2019 | n/a | n/a | -US$1m |
| Mar 31 2019 | n/a | n/a | -US$2m |
| Dec 31 2018 | US$276k | US$275k | -US$2m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$14m |
| Dec 31 2017 | US$275k | US$275k | -US$15m |
Rémunération vs marché: David's total compensation ($USD225.00K) is below average for companies of similar size in the US market ($USD680.04K).
Rémunération et revenus: David's compensation has increased whilst the company is unprofitable.
PDG
David Jorden (62 yo)
9.3yrs
Titularisation
US$225,000
Compensation
Mr. David E. Jorden, CPA has been the Chief Executive Officer and Chief Financial Officer of Nuo Therapeutics, Inc. since July 1, 2016 and serves as its Secretary and was its Acting Chief Executive Officer...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, CFO | 9.3yrs | US$225.00k | 4.34% $ 789.7k | |
| COO & Chief Scientific Officer | 2.6yrs | US$225.00k | 1.3% $ 235.8k | |
| Informal Board Advisor | no data | US$27.50k | pas de données |
7.3yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Gestion expérimentée: AURX's management team is seasoned and experienced (7.3 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, CFO | 15.8yrs | US$225.00k | 4.34% $ 789.7k | |
| Independent Director | 15.6yrs | US$1.07k | 0.055% $ 10.0k | |
| Member of Scientific Advisory Board | 13.7yrs | pas de données | pas de données | |
| Independent Director | 7.3yrs | US$1.07k | 0% $ 0 | |
| Member of Scientific Advisory Board | 13.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 13.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 13.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 13.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 13.7yrs | pas de données | pas de données | |
| Independent Director | 8.3yrs | US$1.43k | 11.39% $ 2.1m |
13.7yrs
Durée moyenne de l'emploi
66.5yo
Âge moyen
Conseil d'administration expérimenté: AURX's board of directors are seasoned and experienced ( 13.7 years average tenure).